Literature DB >> 1503439

Antimicrotubule benzimidazoles inhibit in vitro growth of Pneumocystis carinii.

M S Bartlett1, T D Edlind, M M Durkin, M M Shaw, S F Queener, J W Smith.   

Abstract

Nine antimicrotubule benzimidazole derivatives tested in a Pneumocystis carinii culture system with human embryonic lung fibroblast monolayers inhibited organism proliferation. The concentrations of drugs inhibitory in culture ranged from 10 to 0.1 micrograms/ml, with thiabendazole being the least effective (10 micrograms/ml) and parbendazole being the most effective (0.1 microgram/ml). The parent compound, benzimidazole, was inactive at 10 micrograms/ml. Demonstration that this group of compounds has activity against P. carinii provides a new potential target that can be exploited, the microtubules. Also, the variability in the effectiveness of the compounds provides the basis for studies of structure-activity relationships, which were initiated in this study.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1503439      PMCID: PMC189407          DOI: 10.1128/AAC.36.4.779

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  17 in total

1.  Dexamethasone increases plasma levels of albendazole.

Authors:  H Jung; M Hurtado; M T Medina; M Sanchez; J Sotelo
Journal:  J Neurol       Date:  1990-08       Impact factor: 4.849

2.  Activity of the anthelmintic benzimidazoles against Giardia lamblia in vitro.

Authors:  T D Edlind; T L Hang; P R Chakraborty
Journal:  J Infect Dis       Date:  1990-12       Impact factor: 5.226

Review 3.  The role of the cytoskeletal protein, tubulin, in the mode of action and mechanism of drug resistance to benzimidazoles.

Authors:  E Lacey
Journal:  Int J Parasitol       Date:  1988-11       Impact factor: 3.981

4.  Antimicrobial susceptibility of Pneumocystis carinii in culture.

Authors:  M S Bartlett; R Eichholtz; J W Smith
Journal:  Diagn Microbiol Infect Dis       Date:  1985-09       Impact factor: 2.803

5.  Clindamycin and primaquine as primary treatment for mild and moderately severe Pneumocystis carinii pneumonia in patients with AIDS.

Authors:  J R Black; J Feinberg; R L Murphy; R J Fass; J Carey; F R Sattler
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-03       Impact factor: 3.267

6.  Clindamycin with primaquine for Pneumocystis carinii pneumonia.

Authors:  E Toma; S Fournier; M Poisson; R Morisset; D Phaneuf; C Vega
Journal:  Lancet       Date:  1989-05-13       Impact factor: 79.321

7.  8-Aminoquinolines from Walter Reed Army Institute for Research for treatment and prophylaxis of Pneumocystis pneumonia in rat models.

Authors:  M S Bartlett; S F Queener; R R Tidwell; W K Milhous; J D Berman; W Y Ellis; J W Smith
Journal:  Antimicrob Agents Chemother       Date:  1991-02       Impact factor: 5.191

8.  Pneumocystis carinii: improved models to study efficacy of drugs for treatment or prophylaxis of Pneumocystis pneumonia in the rat (Rattus spp.).

Authors:  M S Bartlett; J A Fishman; M M Durkin; S F Queener; J W Smith
Journal:  Exp Parasitol       Date:  1990-01       Impact factor: 2.011

9.  Complications of co-trimoxazole in treatment of AIDS-associated Pneumocystis carinii pneumonia in homosexual men.

Authors:  H S Jaffe; D I Abrams; A J Ammann; B J Lewis; J A Golden
Journal:  Lancet       Date:  1983-11-12       Impact factor: 79.321

10.  Activity of inosine analogs against Pneumocystis carinii in culture.

Authors:  M S Bartlett; J J Marr; S F Queener; R S Klein; J W Smith
Journal:  Antimicrob Agents Chemother       Date:  1986-07       Impact factor: 5.191

View more
  12 in total

Review 1.  Treatment of infection due to Pneumocystis carinii.

Authors:  J A Fishman
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

2.  Localization of cytoskeletal proteins in Pneumocystis carinii by immuno-electron microscopy.

Authors:  J R Yu; J K Pyon; M Seo; B S Jung; S R Cho; S H Lee; S T Hong
Journal:  Korean J Parasitol       Date:  2001-03       Impact factor: 1.341

3.  Activities and conformational fitting of 1,4-naphthoquinone derivatives and other cyclic 1,4-diones tested in vitro against Pneumocystis carinii.

Authors:  M D Ball; M S Bartlett; M Shaw; J W Smith; M Nasr; S R Meshnick
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

4.  IMP dehydrogenase from Pneumocystis carinii as a potential drug target.

Authors:  M J O'Gara; C H Lee; G A Weinberg; J M Nott; S F Queener
Journal:  Antimicrob Agents Chemother       Date:  1997-01       Impact factor: 5.191

5.  In vitro susceptibility of the opportunistic fungus Cryptococcus neoformans to anthelmintic benzimidazoles.

Authors:  M C Cruz; M S Bartlett; T D Edlind
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

6.  Identification of a class of sulfonamides highly active against dihydropteroate synthase form Toxoplasma gondii, Pneumocystis carinii, and Mycobacterium avium.

Authors:  L C Chio; L A Bolyard; M Nasr; S F Queener
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

7.  Activity of topoisomerase inhibitors against Pneumocystis carinii in vitro and in an inoculated mouse model.

Authors:  J A Fishman; S F Queener; R S Roth; M S Bartlett
Journal:  Antimicrob Agents Chemother       Date:  1993-07       Impact factor: 5.191

8.  Evaluation of potent inhibitors of dihydrofolate reductase in a culture model for growth of Pneumocystis carinii.

Authors:  M S Bartlett; M Shaw; P Navaran; J W Smith; S F Queener
Journal:  Antimicrob Agents Chemother       Date:  1995-11       Impact factor: 5.191

9.  8-aminoquinolines effective against Pneumocystis carinii in vitro and in vivo.

Authors:  S F Queener; M S Bartlett; M Nasr; J W Smith
Journal:  Antimicrob Agents Chemother       Date:  1993-10       Impact factor: 5.191

10.  Albendazole inhibits Pneumocystis carinii proliferation in inoculated immunosuppressed mice.

Authors:  M S Bartlett; T D Edlind; C H Lee; R Dean; S F Queener; M M Shaw; J W Smith
Journal:  Antimicrob Agents Chemother       Date:  1994-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.